Vaccine. 2009 Oct 23;27(45):6291-5.

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.

Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.

Source

University of Tampere Medical School, Medical School/FM3, 33014 Tampere, Finland. timo.vesikari@uta.fi

Abstract

After priming with two intramuscular doses of MF59-adjuvanted (Sub/MF59) or split influenza vaccines during the 2006/07 season, 89 healthy children received a third booster dose of the respective vaccine (2007/08 Northern Hemisphere formulation) approximately 1 year later, and were followed up for 6 months post-third injection. Immunogenicity was evaluated on 81 of them by a hemagglutination inhibition (HI) assay before and 3 weeks after vaccination. The Sub/MF59 influenza vaccine was safe and well tolerated following the booster vaccination. Pre-booster HI antibody titers were consistently higher in the Sub/MF59 group than in the comparator group, confirming significantly longer persistence of antibodies after priming with Sub/MF59 vaccine. Post-booster immune responses were significantly higher in the Sub/MF59 group compared with the split group, especially vs. the influenza B strain, which is epidemiologically relevant in the pediatric population. Altogether, these data further support the potential use of MF59-adjuvanted influenza vaccine as a safe and highly immunogenic influenza vaccine for young children.

PMID:: 19840662; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Flu - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. [Pediatr Infect Dis J. 2009]
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Pediatr Infect Dis J. 2009 Jul; 28(7):563-71.
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. [N Engl J Med. 2009]
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. N Engl J Med. 2009 Dec 17; 361(25):2424-35. Epub 2009 Sep 10.
Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. [Clin Vaccine Immunol. 2011]
Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ. Clin Vaccine Immunol. 2011 Aug; 18(8):1358-64. Epub 2011 Jun 29.
Review MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. [Influenza Other Respi Viruses....]
Review MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.
Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. Influenza Other Respi Viruses. 2008 Nov; 2(6):243-9.
Review MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. [Expert Rev Vaccines. 2007]
Review MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
Puig Barberà J, González Vidal D. Expert Rev Vaccines. 2007 Oct; 6(5):659-65.

See reviews... See all...

Cited by 7 PubMed Central articles

Towards universal influenza vaccines? [Philos Trans R Soc Lond B Biol...]
Towards universal influenza vaccines?
Osterhaus A, Fouchier R, Rimmelzwaan G. Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12; 366(1579):2766-73.
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. [Clin Vaccine Immunol. 2011]
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population.
Huijskens E, Rossen J, Mulder P, van Beek R, van Vugt H, Verbakel J, Rimmelzwaan G, Koopmans M, Peeters M. Clin Vaccine Immunol. 2011 Sep; 18(9):1401-5. Epub 2011 Jul 27.
An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines. [J Drug Deliv. 2011]
An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.
Salvador A, Igartua M, Hernández RM, Pedraz JL. J Drug Deliv. 2011; 2011:181646. Epub 2011 Jun 15.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity...
MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vaccine. 2009 Oct 23 ;27(45):6291-5.

PubMed
Potential roles and clinical utility of prebiotics in newborns, infants, and chi...
Potential roles and clinical utility of prebiotics in newborns, infants, and children: proceedings from a global prebiotic summit meeting, New York City, June 27-28, 2008.
J Pediatr. 2009 Nov ;155(5):S61-70.

PubMed
Brief cognitive-behavioral therapy with fibromyalgia patients in routine care.
Brief cognitive-behavioral therapy with fibromyalgia patients in routine care.
Compr Psychiatry. 2009 Nov-Dec ;50(6):517-25. Epub 2009 Mar 12 .

PubMed
Viral infection leading to brain dysfunction: more prevalent than appreciated?
Viral infection leading to brain dysfunction: more prevalent than appreciated?
Neuron. 2009 Oct 15 ;64(1):17-20.

PubMed
Repeat tuberculin skin testing leads to desensitisation in naturally infected tu...
Repeat tuberculin skin testing leads to desensitisation in naturally infected tuberculous cattle which is associated with elevated interleukin-10 and decreased interleukin-1 beta responses.
Vet Res. 2010 Mar-Apr ;41(2):14. Epub 2009 Oct 20 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.

Source

Abstract

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information